HomeInsightsStock Comparison

Elixir Capital Ltd vs Novelix Pharmaceuticals Ltd Stock Comparison

Elixir Capital Ltd vs Novelix Pharmaceuticals Ltd Stock Comparison

Last Updated on: May 07, 2025

Key Highlights

  • The Latest Trading Price of Elixir Capital Ltd is ₹ 132.95 as of 07 May 10:32.
  • The P/E Ratio of Elixir Capital Ltd changed from 1.8 on March 2021 to 2.5 on March 2024 . This represents a CAGR of 8.56% over 4 yearsThe P/E Ratio of Novelix Pharmaceuticals Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of Elixir Capital Ltd changed from ₹ 21.32 crore on March 2020 to ₹ 51.24 crore on March 2024 . This represents a CAGR of 19.17% over 5 yearsThe Market Cap of Novelix Pharmaceuticals Ltd changed from ₹ 1.57 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of -100.00% over 5 years.
  • The revenue of Elixir Capital Ltd for the Dec '24 is ₹ 6.26 crore as compare to the Sep '24 revenue of ₹ 18.72 crore. This represent the decline of -66.56% The revenue of Novelix Pharmaceuticals Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 revenue of ₹ 0 crore. This represent the decline of 0%.
  • The ebitda of Elixir Capital Ltd for the Dec '24 is ₹ 2.56 crore as compare to the Sep '24 ebitda of ₹ 15.73 crore. This represent the decline of -83.73% The ebitda of Novelix Pharmaceuticals Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 ebitda of ₹ 0 crore. This represent the decline of 0%.
  • The net profit of Elixir Capital Ltd changed from ₹ 3.06 crore to ₹ 1.19 crore over 7 quarters. This represents a CAGR of -41.71% The net profit of Novelix Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% .
  • The Dividend Payout of Elixir Capital Ltd changed from 109.85 % on March 2020 to 64.73 % on March 2024 . This represents a CAGR of -10.04% over 5 yearsThe Dividend Payout of Novelix Pharmaceuticals Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Elixir Capital Ltd

  • Elixir Capital Ltd., (formerly known Axis Capital Markets (India) Ltd.) is a BSE-listed financial services holding company, which was incorporated in 1994.
  • The Company is also engaged in trading and investment in shares and providing research and advisory services.
  • Their performance is linked to the returns on the stock markets.
  • The Company's directors manage the investment and trading portfolio.
  • The focus is predominantly on small and mid-cap stocks which deliver multiple returns. The primary business activity of the Company involves trading and investment in shares and securities.

About Novelix Pharmaceuticals Ltd

  • Trimurthi Limited was formerly incorporated on December 13, 1994 with the name Trimurthi Securities Ltd. The name of the Company thereafter got changed from Trimurthi Securities Ltd to Trimurthi Drugs & Pharmaceuticals Ltd. In September 2006, as per the Scheme of Arrangement, the erstwhile Trimurthi Drugs & Pharmaceuticals Ltd amalgamated with the Company.
  • Also, the name of the Company was changed to Trimurthi Drugs & Pharmaceuticals Ltd and again to Trimurthi Limited in May, 2016. Initially, the company was engaged in finance and investments in securities.
  • They ceased their operations due to the high volatility in the markets and voluntarily got de-registered as Non-Banking financial company.
  • Thereafter, the company explored the possibilities of entering into pharmaceutical and drug industry by way of diversification.

Elixir Capital Ltd News Hub

News

Elixir Capital announces board meeting date

Elixir Capital will hold a meeting of the Board of Directors of the Company on 7 February ...

Read more

31 Jan 2025 15:49

News

Elixir Capital schedules board meeting

Elixir Capital will hold a meeting of the Board of Directors of the Company on 13 November...

Read more

08 Nov 2024 17:31

News

Elixir Capital to announce Quarterly Result

Elixir Capital will hold a meeting of the Board of Directors of the Company on 13 August 2...

Read more

01 Aug 2024 12:59

News

Elixir Capital to hold AGM

Elixir Capital announced that the Annual General Meeting (AGM) of the company will be held...

Read more

11 Jul 2024 11:01

News

Board of Elixir Capital recommends final dividend

Elixir Capital announced that the Board of Directors of the Company at its meeting held on...

Read more

17 May 2024 09:37

News

Elixir Capital to hold board meeting

Elixir Capital will hold a meeting of the Board of Directors of the Company on 16 May 2024...

Read more

08 May 2024 10:46

Novelix Pharmaceuticals Ltd News Hub

News

Novelix Pharmaceuticals to convene EGM

Novelix Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Comp...

Read more

15 Apr 2025 10:33

News

Trimurthi to table results

Trimurthi will hold a meeting of the Board of Directors of the Company on 12 February 2025...

Read more

08 Feb 2025 10:47

News

Trimurthi to announce Quarterly Result

Trimurthi will hold a meeting of the Board of Directors of the Company on 13 November 2024...

Read more

09 Nov 2024 17:04

News

Trimurthi revises board meeting date

Trimurthi has revised the meeting of the Board of Directors which was scheduled to be held...

Read more

14 Oct 2024 10:29

News

Trimurthi to hold board meeting

Trimurthi will hold a meeting of the Board of Directors of the Company on 14 October 2024....

Read more

08 Oct 2024 10:44

News

Trimurthi schedules AGM

Trimurthi announced that the Annual General Meeting (AGM) of the company will be held on 2...

Read more

14 Sep 2024 17:30

SWOT Analysis Of Novelix Pharmaceuticals Ltd

Strength

0

S

Weakness

0

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Elixir Capital Ltd

Strength

1

S

Weakness

0

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Novelix Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Elixir Capital Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Elixir Capital Ltd and Novelix Pharmaceuticals Ltd

Which company has a larger market capitalization, Elixir Capital Ltd or Novelix Pharmaceuticals Ltd?

Market cap of Elixir Capital Ltd is 74 Cr while Market cap of Novelix Pharmaceuticals Ltd is 66 Cr

What are the key factors driving the stock performance of Elixir Capital Ltd and Novelix Pharmaceuticals Ltd?

The stock performance of Elixir Capital Ltd and Novelix Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Elixir Capital Ltd and Novelix Pharmaceuticals Ltd?

As of May 7, 2025, the Elixir Capital Ltd stock price is INR ₹127.9. On the other hand, Novelix Pharmaceuticals Ltd stock price is INR ₹26.61.

How do dividend payouts of Elixir Capital Ltd and Novelix Pharmaceuticals Ltd compare?

To compare the dividend payouts of Elixir Capital Ltd and Novelix Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions